Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585776 · ClinicalTrials.gov registry record · Phase 2
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04585776 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 31 participants.
The verdict
NCT04585776, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
Interventions
- DRUG Insulin Degludec
- DRUG LY900014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2021-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04585776
The ClinicalTrials.gov registry entry for NCT04585776 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Degludec is the first listed.
NCT04585776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04585776 about?
NCT04585776 is a clinical study titled "A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes". In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
What is the current status of trial NCT04585776?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-10-30. Estimated completion is 2021-05-27.
What interventions are being tested in trial NCT04585776?
The interventions under investigation include: Insulin Degludec (DRUG), LY900014 (DRUG).
Who is sponsoring clinical trial NCT04585776?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.